one clarification I would like to add to your analysis -...

one clarification I would like to add to your analysis - assuming we are understanding AT1's account & reporting method correctly:

- Q1 FY22 = $2.2m (HIV + OEM + Ag)
- sales reported in Q1 FY22 = $2.4m (presuming Ag + HIV) = we already are exceeding Q1 FY22 (and Q4 FY21) receipts nicely?

So assuming HIV + Ag sales continue strongly through Q2 FY22 = mid-year FY22 receipts should be >50% of FY21 half-yearly (estimate $6-7m?)

Speculation: if the 10m professional + 10m self-test Ag kits are able to be sold by Dec'21, this should significantly boost FY22 half-yearly to much higher levels? For now, the trend looks like it will exceed FY21 mid-year $ comfortably. Whether it can significantly exceed it, we can gauge better after self-test approvals & any further large HIV/Ag order news comes through.